ASCO Annual Meeting - American Society of Clinical Oncology Annual Meeting

Trastuzumab deruxtecan shows superior and clinically meaningful progression-free survival and overall survival benefit in patients with HER2-low unresectable and/or metastatic breast cancer with hormone receptor-positive or negative disease.

Three-year follow-up analysis shows that Gilead’s car T-cell therapy induced high rates of durable response and a median overall survival of 46.6 months.

Sacituzumab govitecan-hziy (Trodelvy) found to lower the risk of disease progression or death by 34% in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

AstraZeneca trial results shows 90% of patients with chronic lymphocytic leukemia surviving for 5 years.

Kelly McAuliff, PharmD, BCOP, CSP, spoke about research into the impacts of the COVID-19 pandemic on oral oncolytic adherence, particularly for patients with ovarian cancer, prostate cancer, or chronic myelogenous leukemia.

Both patients and providers should recognize the benefits of early referrals to palliative care.

With several recent approvals, new CAR T therapies are having significant impacts in multiple myeloma treatment.

With a median follow-up of 90 months, individuals receiving palbociclib in combination with letrozole had numerically longer OS compared to placebo, but it was not deemed statistically significant.

Overall outcomes were consistent with axicabtagene ciloleucel in the real-world setting, regardless of race or ethnicity, in adults with relapsed or refractory large B-cell lymphoma.

Brentuximab vedotin (Adcetris) plus doxorubicin, vinblastine, and dacarbazine shows improved overall survival compared with standard chemotherapy in patients with previously untreated, advanced stage classical Hodgkin lymphoma.

An immune checkpoint inhibitor plus ramucirumab found to improve overall survival versus standard of care in patients with advanced non-small cell lung cancer.

Ibrutinib plus bendamustine-rituximab and rituximab maintenance was found to lower the risk of disease progression or death by 25% compared with placebo in patients 65 years of age or older with newly diagnosed mantle cell lymphoma.

Uliledlimab plus toripalimab (Tuoyi) shows significant response rates in patients with advanced non–small cell lung cancer previously ineligible to receive standard-of-care treatment.

Analysis shows that different genetic mutation profiles in tumors harboring PIK3CA mutation did not affect the treatment benefit with alpelisib (Piqray) combined with fulvestrant in individuals with HR+/HER2- advanced or metastatic breast cancer.

Improvement in recurrence-free survival was seen primarily in individuals with very high-risk renal cell carcinoma, whereas individuals with intermediate high-risk disease showed no improvements in survival.

The median overall survival was 66 months for individuals with hormone receptor-positive/human epidermal growth factor receptor-negative advanced or metastatic breast cancer administered at least 1 dose reduction of ribociclib (Kisqali) from the starting dose of 600 mg.

Company releases data at the American Society of Clinical Oncology Annual Meeting 2022 showing that the drug is well-tolerated in patients with solid tumors.

Pharmacy Times will be covering the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting live in Chicago, Illinois, from June 3 through 7, 2022.

We spoke with Kelly McAuliff, PharmD, BCOP, CSP, to learn about data being presented at the ASCO 2022 Annual Meeting.

Primary results from the randomized portion of the INVICTUS study had previously shown that ripretinib was able to significantly improve progression-free survival with a clinically meaningful overall survival benefit in patients with advanced gastrointestinal stromal tumor.

The study examining venetoclax and obinutuzumab is in progress and currently recruiting patients who are newly diagnosed with asymptomatic, high-risk CLL.

Data were presented at the virtual 2021 American Society of Clinical Oncology (ASCO) Annual Conference.

Data from a phase 3 trial comparing acalabrutinib against ibrutinib in adults with previously treated CLL showed acalabrutinib presented with non-inferior PFS and significantly fewer events of atrial fibrillation.

Phase 3 data presented at the 2021 ASCO Annual Meeting have reinforced the long-term survival benefits and well-established safety profile of single-agent ibrutinib for patients with CLL.

Nivolumab and ipilimumab is the first dual immunotherapy combination to demonstrate a superior survival benefit compared to chemotherapy in this setting.

Patients with prostate cancer have to be approached differently depending on the state of their metastases.

Analysis from the phase 3 ANDROMEDA study also shows doubling rates of organ response with no new safety signals for patients taking daratumumab and hyaluronidase-fihj.

Although historic study results with mantel cell lymphoma showed discouraging findings, new CAR T-cell therapies routinely show between 40% and 50% of patients respond long-term without relapsing.

Investigative and newly approved drugs targeting RET activity and KRAS-related mutations are showing deep, durable responses in several types of cancers.

While discussing a few case studies, the panel was able to make appropriate treatment decisions for each patient and emphasized the importance of communicating with patients as a physician.